Latest Capital Markets News

The ASX has released its latest list of entities suspended for over three months, outlining critical deadlines for outstanding report lodgements and potential removal from the official list.

Vinyl Group Ltd has updated the timeline for its Entitlements Offer, delaying the final allotment of underwritten shortfall securities to January 28, 2025, with shares to be listed the following day.

BPH Energy Limited's December 2024 quarterly report reveals strategic capital placements and investments in hydrogen and medical technology, alongside ongoing regulatory challenges with the PEP-11 permit.

Paladin Energy reports its highest monthly uranium production since March 2024 and completes the strategic acquisition of Fission Uranium Corp, expanding its footprint in Canada’s uranium sector.

Pentanet Ltd reported a positive cash flow from operations of $860,000 for the December 2024 quarter, maintaining a healthy cash balance of $2.22 million despite significant capital expenditures including a $1.6 million payment for a 5G spectrum license.

Zeus Resources has successfully placed the shortfall in its Priority Options Offer, bringing total funds raised to nearly $200,000. The move reflects solid shareholder backing ahead of the company’s next growth phase.

Wellnex Life has negotiated a delayed and reduced-cost payment arrangement for its Pain Away acquisition, aligning with its upcoming London Stock Exchange dual listing plans. The move supports the company’s growth momentum following record revenues from Pain Away.

5E Advanced Materials has entered a pivotal Restructuring Support Agreement with its primary lenders to equitize $63.5 million in convertible notes and secure up to $30 million in funding. The transaction, subject to shareholder approval, aims to strengthen the balance sheet and advance the company toward its Final Investment Decision.

5E Advanced Materials has announced a $30 million funding package alongside a significant restructuring of its convertible notes, aiming to strengthen its balance sheet and advance toward a Final Investment Decision.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

Cardno Limited has requested an immediate suspension from ASX quotation to facilitate its removal from the official ASX list, marking a significant step in its delisting process.

The Supreme Court of New South Wales has approved the scheme of arrangement for Southern Cross Gold Consolidated Ltd to acquire all remaining shares of Southern Cross Gold Ltd, setting the stage for a significant ownership consolidation and ASX trading changes.